Aileron Therapeutics Inc (Aileron Therapeutics) is a biopharmaceutical company. The company develops medicines to make chemotherapy safer and thereby more effective to save more patients’ lives. Its products include ALRN-6924 MDM2 and MDMX dual inhibitor a chemoprotective agent that treats patients with p53-mutated cancers. It also provides radioprotection, anti-cancer research and discovery research. The company partners with research organizations to provide its products. Aileron Therapeutics is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
12407 N. Mopac Expy., Suite 250 #390, Austin, Texas, 78758
Website
aileronrx.com
Telephone
1 617 9950900
No of Employees
6
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALRN (NASD)
EPS
XYZ
Net Income (2021)
XYZ
-4.5%
(2021 vs 2020)
Market Cap*
$83.7M
Net Profit Margin (0 vs)
XYZ
0.0%
(2021 vs 2020)
* As of and is in US$
Products and Services
| Products |
|---|
| Stapled Peptide Drugs: ALRN-6924 |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company acquired Lung Therapeutics, Inc., a biopharmaceutical company. |
| 2018 | Contracts/Agreements | In November, the company collaborated with Pfizer to evaluate ALRN-6924 in combination with Ibrance (palbociclib) to treat MDM2-Amplified Cancers. |
| 2017 | Stock Listings/IPO | In June, the company plans to raise IPO of shares for US$69 million. |
Competitor Comparison
| Key Parameters | Aileron Therapeutics Inc | Abeona Therapeutics Inc | Seelos Therapeutics, Inc. | Black Diamond Therapeutics Inc | iCeutica Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Austin | Cleveland | New York | Cambridge | Princeton |
| State/Province | Texas | Ohio | New York | Massachusetts | New Jersey |
| No. of Employees | 6 | 84 | 15 | 54 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeffrey A. Bailey | Chairman | Executive Board | 2018 | 61 |
| Christopher Zergebel | Vice President - Program Management and Clinical Operations | Senior Management | 2022 | - |
| Andres Brainsky, M.D. | Vice President - Clinical Development | Senior Management | 2021 | - |
| Susan Drexler | Chief Financial Officer - Interim | Senior Management | 2022 | 53 |
| Allen Annis, Ph.D. | Senior Vice President - Research | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer